1AI
Algorae Pharmaceuticals Limited
🇦🇺 ASX
🧬 BIOTECHNOLOGY
👑 Overview
📈 Performance
💵 Cost
🤓 Advanced
👨👩👧👦 Community
📈
-12.22%
Annual Growth
5 years average annual growth
💵
$ 500
Minimum Order
Due to regulatory requirements
🌏
3
Pearlers Invested
Since January 2020
👑 Overview
Key information
🔎 Fund Overview
Algorae Pharmaceuticals Ltd. is a biotechnology company, which engages in the development of treatments for implanting healthy living cells to replace or repair diseased or damaged organs for life threatening diseases. The company is headquartered in Melbourne, Victoria. The company went IPO on 2004-09-01. The firm is focused on discovering and developing novel treatments for medical conditions with under met medical needs. Its programs include AlgoraeOS, Dementia and Parkinson’s. Its drug candidates include NTCELL for Parkinson’s disease and the AI-116 combination drug candidate for dementia. AlgoraeOS is a closed-loop platform, leveraging advanced computational tools to generate novel insights in-silico that are being developed to initiate or accelerate therapeutic programs. The AI-116 is a novel combination drug candidate made up of cannabidiol (CBD) and an off-patent pharmaceutical ingredient. The NTCELL is an alginate coated capsule product containing clusters of neonatal porcine choroid plexus cells that are injected into the damaged site within the brain to target the treatment of Parkinson’s disease.
📈 Performance
Price History
-88.71%
1M
1Y
10Y
Graph
Table
Unsure how much or often to invest?
🗓️ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out →💵 Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out →⏱️ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out →💵 Costs
💼
0%
Management Fee
Included in unit price, not charged by Pearler
💸
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator🤓 Advanced information
Technical Info
💰 Price*
$0.01
*Price may be up to 24 hours old
👩👩👦 Community Insights
How our community is investing
🌏 Pearlers invested in 1AI
3
📊 Total Capital Earnings
$1K
🔃 Average investment frequency
7 weeks
💵 Average investment amount
$5,180
⏰ Last time a customer invested in 1AI
56 days
1AI investor breakdown
💵 Income of investors
More than 200k
150k - 200k
25%
100k - 150k
50%
50k - 100k
Less than 50k
25%
👶 Age of investors
18 - 25
26 - 34
35 - 90
100%
🙋 Legal gender of investors
Female
33%
Male
67%
Pearlers who invest in 1AI also invest in...
VAS.AX was created on 2009-05-04 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard Australian Shares Index ETF seeks to track the return of the S&P/ASX 300 Index before taking into account fees, expenses and tax.
🙌 Performance (5Yr p.a)
3.82%
📊 Share price
$102.75 AUD
🇦🇺 AUSTRALIA
💸 FINANCIALS
🧱 MATERIALS
⛳️ DIVERSIFIED
VGS.AX was created on 2014-11-18 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard MSCI International Shares Index ETF seeks to track the return of the MSCI World ex-Australia Index (with net dividends reinvested) in Australian dollars before taking into account fees, expenses and tax.
🙌 Performance (5Yr p.a)
12.24%
📊 Share price
$126.50 AUD
🌏 GLOBAL
🤖 TECHNOLOGY
⛳️ DIVERSIFIED
📈 HIGH PRICE GROWTH
Living Cell Technologies Ltd. is a biotechnology company, which engages in the development of treatments for implanting healthy living cells to replace or repair diseased or damaged organs for life threatening diseases. The company is headquartered in Melbourne, Victoria. The company went IPO on 2004-09-01. The firm is focused on discovering and developing treatments for conditions, such as diabetes and Parkinson's disease. The company operates in both Australia and New Zealand, being the research and development and product development into living cell technologies. The firm's product candidate includes NTCELL, an alginate coated capsule containing clusters of neonatal porcine choroid plexus cells targeting Parkinson’s disease. Choroid plexus cells are naturally occurring support cells for the brain and secrete cerebrospinal fluid (CSF), which contains a range of factors that support nerve cell functions and protective enzymes that are crucial for nerve growth and healthy functioning. In NTCELL, the porcine choroid plexus cells are coated with LCT's technology IMMUPEL to protect them from attack by the immune system. The firm has completed two clinical trials of NTCELL in Parkinson's disease.
📊 Share price
$0.01 AUD
ACDC.AX was created on 2018-08-30 by Global X. The fund's investment portfolio concentrates primarily on theme equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the Solactive Battery ValueChain Index (the Index).
🙌 Performance (5Yr p.a)
13.68%
📊 Share price
$80.22 AUD
🤖 TECHNOLOGY
🏭 INDUSTRIALS
🇦🇺 EX AUSTRALIA
📈 HIGH PRICE GROWTH
Want more shares? Try these...
One Click Group Ltd. engages in the provision of financial services. The company is headquartered in Subiaco, Western Australia. The company went IPO on 2017-04-28. The company operates a financial technology platform to handle financial administration tasks, such as lodging tax returns, wills and private health insurance. The Company’s the One Click Life Platform provides taxation preparation software and services in Australia.
🙌 Performance (5Yr p.a)
-18.33%
📊 Share price
$0.01 AUD
👔 PROFESSIONAL SERVICES
AdAlta Ltd. operates as a biotechnology company, discovers, develops, and commercializes protein based therapeutics. The firm uses its i-body platform to discover and develop protein therapeutics addressing drug targets that are challenging for other technologies. The firm's first-in-class lead asset, AD-214, is being developed for the treatment of idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases, for which current therapies are sub-optimal. AD-214 is an Fc-Fusion protein that contains two AD-114 i-body molecules at the front end, that bind with high affinity to the human target, CXCR4. The company is also engaged in developing i-body enabled Chimeric antigen receptor T cell (CAR-T) cells. The company co-develops i-bodies as diagnostic imaging agents (i-PET imaging) against Granzyme B, a biomarker of response to immuno-oncology drugs.
🙌 Performance (5Yr p.a)
-17.44%
📊 Share price
$0.02 AUD
🧬 BIOTECHNOLOGY
Aurora Energy Metals Ltd. engages in the exploration and development of mining properties. The company is headquartered in Subiaco, Western Australia. The company went IPO on 2022-05-18. The AUP is located in Malheur County, Oregon, approximately 16 kilometers (km) northwest of the town of McDermitt, Nevada. The Company’s wholly owned subsidiary, Oregon Energy LLC, holds 100% of the Project as well as surrounding mining claims that extend to the west and to the south-east, across the Oregon/Nevada border. The mining claims are located on public lands in Oregon and Nevada and on a contiguous Company-owned block of private land in Nevada. The land tenure comprises approximately 451 unpatented lode mining claims and 71 unpatented placer mining claims in Malheur County, Oregon and 31 unpatented placer mining claims in Humboldt County, Nevada. The total area covered by these claims is approximately 43 square kilometers. The Project area is covered with a thin veneer of alluvium overlying lakebed sediments.
📊 Share price
$0.04 AUD
⛏️ MINING